A redox-sensitive, oligopeptide-guided, self-assembling, and efficiency-enhanced (ROSE) system for functional delivery of microRNA therapeutics for treatment of hepatocellular carcinoma

Biomaterials

Volumn 104, Issue , 2016, Pages 192-200

  Hu, Qida ^a,b   Wang, Kai ^b   Sun, Xu ^c   Li, Yang ^b   Fu, Qihan ^a   Liang, Tingbo ^a   Tang, Guping ^b  

^a THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^b ZHEJIANG UNIVERSITY   (China)

^c HUZHOU CENTRAL HOSPITAL   (China)

Author keywords

Delivery system; Hepatocellular carcinoma; miRNA therapy; Multifunctional delivery

Indexed keywords

CELL PROLIFERATION; COVALENT BONDS; EFFICIENCY; GENE TRANSFER; GENES; MOLECULAR BIOLOGY; NANOPARTICLES; NANOSYSTEMS; RNA; SELF ASSEMBLY; TUMORS;

ADJUVANT TREATMENT; CONTROLLED RELEASE; DELIVERY SYSTEMS; HEPATOCELLULAR CARCINOMA; MIRNA THERAPY; MULTIFUNCTIONAL DELIVERY; SUPRAMOLECULAR COMPLEXES; THERAPEUTIC AGENTS;

GENE THERAPY;

MICRORNA 34A; NANOPARTICLE; POLYCATION; MICRORNA; MIRN34 MICRORNA, HUMAN; NANOCAPSULE; OLIGOPEPTIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISULFIDE BOND; EPITHELIAL MESENCHYMAL TRANSITION; GENE DELIVERY SYSTEM; GENETIC TRANSFECTION; IN VITRO STUDY; LIVER CELL CARCINOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; REDOX SENSITIVE OLIGOPEPTIDE GUIDED SELF ASSEMBLING AND EFFICIENCY ENHANCED SYSTEM; TUMOR GROWTH; TUMOR VOLUME; ANIMAL; CHEMISTRY; CRYSTALLIZATION; DRUG POTENTIATION; GENE THERAPY; GENETICS; METABOLISM; OXIDATION REDUCTION REACTION; PROCEDURES; TREATMENT OUTCOME; TUMOR CELL LINE; ULTRASTRUCTURE;

ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CRYSTALLIZATION; DRUG SYNERGISM; GENETIC THERAPY; MICE; MICRORNAS; NANOCAPSULES; OLIGOPEPTIDES; OXIDATION-REDUCTION; TREATMENT OUTCOME;

EID: 84978792978     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2016.07.016     Document Type: Article

References (41)

1. [1] Bruix, J., Gores, G.J., Mazzaferro, V., Hepatocellular carcinoma: clinical frontiers and perspectives. Gut 63 (2014), 844–855.
2. [2] Cheng, A.L., Kang, Y.K., Chen, Z., Tsao, C.J., Qin, S., Kim, J.S., et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol. 10 (2009), 25–34.
3. [3] Yeo, W., Mok, T.S., Zee, B., Leung, T.W., Lai, P.B., Lau, W.Y., et al. A randomized phase III study of doxorubicin versus cisplatin/interferon α-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J. Natl. Cancer Inst. 97 (2005), 1532–1538.
4. [4] Thomas, M.B., O'Beirne, J.P., Furuse, J., Chan, A.T., Abou-Alfa, G., Johnson, P., Systemic therapy for hepatocellular carcinoma: cytotoxic chemotherapy, targeted therapy and immunotherapy. Ann. Surg. Oncol. 15 (2008), 1008–1014.
5. [5] Jackson, A.L., Linsley, P.S., Recognizing and avoiding siRNA off-target effects for target identification and therapeutic application. Nat. Rev. Drug Discov. 9 (2010), 57–67.
6. [6] Singh, S., Narang, A.S., Mahato, R.I., Subcellular fate and off-target effects of siRNA, shRNA, and miRNA. Pharm. Res. 28 (2011), 2996–3015.
7. [7] Bader, A.G., Brown, D., Winkler, M., The promise of microRNA replacement therapy. Cancer Res. 70 (2010), 7027–7030.
8. [8] Chang, T.C., Wentzel, E.A., Kent, O.A., Ramachandran, K., Mullendore, M., Lee, K.H., et al. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol. Cell. 26 (2007), 745–752.
9. [9] Misso, G., Di Martino, M.T., De Rosa, G., Farooqi, A.A., Lombardi, A., Campani, V., et al. Mir-34: a new weapon against cancer?. Mol. Ther. Nucleic Acids, 3, 2014, e194.
10. [10] Daige, C.L., Wiggins, J.F., Priddy, L., Nelligan-Davis, T., Zhao, J., Brown, D., Systemic delivery of a miR34a mimic as a potential therapeutic for liver cancer. Mol. Cancer Ther. 13 (2014), 2352–2360.
11. [11] Hu, Q.D., Tang, G.P., Chu, P.K., Cyclodextrin-based host-guest supramolecular nanoparticles for delivery: from design to applications. Acc. Chem. Res. 47 (2014), 2017–2025.
12. [12] Tang, G.P., Guo, H.Y., Alexis, F., Wang, X., Zeng, S., Lim, T.M., et al. Low molecular weight polyethylenimines linked by β-cyclodextrin for gene transfer into the nervous system. J. Gene Med. 8 (2006), 736–744.
13. [13] Li, D., Li, Y., Xing, H., Guo, J., Ping, Y., Tang, G., Synergistic enhancement of lung cancer therapy through nanocarrier-mediated sequential delivery of superantigen and tyrosin kinase inhibitor. Adv. Funct. Mater. 24 (2014), 5482–5492.
14. [14] Ping, Y., Hu, Q., Tang, G., Li, J., FGFR-targeted gene delivery mediated by supramolecular assembly between β-cyclodextrin-crosslinked PEI and redox-sensitive PEG. Biomaterials 34 (2013), 6482–6494.
15. [15] Hu, Q.D., Fan, H., Ping, Y., Liang, W.Q., Tang, G.P., Li, J., Cationic supramolecular nanoparticles for co-delivery of gene and anticancer drug. Chem. Commun. 47 (2011), 5572–5574.
16. [16] Akinc, A., Thomas, M., Klibanov, A.M., Langer, R., Exploring polyethylenimine-mediated DNA transfection and the proton sponge hypothesis. J. Gene Med. 7 (2005), 657–663.
17. [17] Ogris, M., Brunner, S., Schuller, S., Kircheis, R., Wagner, E., PEGylated DNA/transferrin-PEI complexes: reduced interaction with blood components, extended circulation in blood and potential for systemic gene delivery. Gene Ther. 6 (1999), 595–605.
18. [18] Davis, M.E., Zuckerman, J.E., Choi, C.H., Seligson, D., Tolcher, A., Alabi, C.A., et al. Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature 464 (2010), 1067–1070.
19. [19] Chen, G., Jiang, M., Cyclodextrin-based inclusion complexation bridging supramolecular chemistry and macromolecular self-assembly. Chem. Soc. Rev. 40 (2011), 2254–2266.
20. [20] Jokerst, J.V., Lobovkina, T., Zare, R.N., Gambhir, S.S., Nanoparticle PEGylation for imaging and therapy. Nanomedicine 6 (2011), 715–728.
21. [21] Zhang, Z.X., Liu, X., Xu, F.J., Loh, X.J., Kang, E.T., Neoh, K.G., et al. Pseudo-block copolymer based on star-shaped poly(N-isopropylacrylamide) with a β-cyclodextrin core and guest-bearing PEG: controlling thermoresponsivity through supramolecular self-assembly. Macromolecules 41 (2008), 5967–5970.
22. [22] Lo, A., Lin, C.T., Wu, H.C., Hepatocellular carcinoma cell-specific peptide ligand for targeted drug delivery. Mol. Cancer Ther. 7 (2008), 579–589.
23. [23] Ogris, M., Steinlein, P., Kursa, M., Mechtler, K., Kircheis, R., Wagner, E., The size of DNA/transferrin-PEI complexes is an important factor for gene expression in cultured cells. Gene Ther. 5 (1998), 1425–1433.
24. [24] Elsabahy, M., Wooley, K.L., Design of polymeric nanoparticles for biomedical delivery applications. Chem. Soc. Rev. 41 (2012), 2545–2561.
25. [25] Saito, G., Swanson, J.A., Lee, K.D., Drug delivery strategy utilizing conjugation via reversible disulfide linkages: role and site of cellular reducing activities. Adv. Drug Deliv. Rev. 55 (2003), 199–215.
26. [26] Remaut, K., Lucas, B., Raemdonck, K., Braeckmans, K., Demeester, J., De Smedt, S.C., Protection of oligonucleotides against enzymatic degradation by pegylated and nonpegylated branched polyethyleneimine. Biomacromolecules 8 (2007), 1333–1340.
27. [27] MacKay, J.A., Chen, M., McDaniel, J.R., Liu, W., Simnick, A.J., Chilkoti, A., Self-assembling chimeric polypeptide-doxorubicin conjugate nanoparticles that abolish tumours after a single injection. Nat. Mater 8 (2009), 993–999.
28. [28] Kottke, T., Boisgerault, N., Diaz, R.M., Donnelly, O., Rommelfanger-Konkol, D., Pulido, J., et al. Detecting and targeting tumor relapse by its resistance to innate effectors at early recurrence. Nat. Med. 19 (2013), 1625–1631.
29. [29] Giancotti, F.G., Mechanisms governing metastatic dormancy and reactivation. Cell. 155 (2013), 750–764.
30. [30] Kim, S., Shi, Y., Kim, J.Y., Park, K., Cheng, J.X., Overcoming the barriers in micellar drug delivery: loading efficiency, in vivo stability, and micelle-cell interaction. Expert Opin. Drug Deliv. 7 (2010), 49–62.
31. [31] Fuchs, B.C., Fujii, T., Dorfman, J.D., Goodwin, J.M., Zhu, A.X., Lanuti, M., et al. Epithelial-to-mesenchymal transition and integrin-linked kinase mediate sensitivity to epidermal growth factor receptor inhibition in human hepatoma cells. Cancer Res. 68 (2008), 2391–2399.
32. [32] Hu, Q.D., Chen, W., Yan, T.L., Ma, T., Chen, C.L., Liang, C., et al. NSC 74859 enhances doxorubicin cytotoxicity via inhibition of epithelial-mesenchymal transition in hepatocellular carcinoma cells. Cancer Lett. 325 (2012), 207–213.
33. [33] Ell, B., Kang, Y., Transcriptional control of cancer metastasis. Trends Cell Biol. 23 (2013), 603–611.
34. [34] Bader, A.G., miR-34-a microRNA replacement therapy is headed to the clinic. Front. Genet., 3, 2012, 120.
35. 13C-labelled bicarbonate. Nature 453 (2008), 940–943.
36. [36] Kelly, K.A., Bardeesy, N., Anbazhagan, R., Gurumurthy, S., Berger, J., Alencar, H., et al. Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med., 5, 2008, e85.
37. [37] Mintzer, M.A., Simanek, E.E., Nonviral vectors for gene delivery. Chem. Rev. 109 (2009), 259–302.
38. [38] Rokavec, M., Oner, M.G., Li, H., Jackstadt, R., Jiang, L., Lodygin, D., et al. IL-6R/STAT3/miR-34a feedback loop promotes EMT-mediated colorectal cancer invasion and metastasis. J. Clin. Investig. 124 (2014), 1853–1867.
39. [39] Li, N., Fu, H., Tie, Y., Hu, Z., Kong, W., Wu, Y., et al. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett. 275 (2009), 44–53.
40. [40] Yamakuchi, M., Ferlito, M., Lowenstein, C.J., miR-34a repression of SIRT1 regulates apoptosis. Proc. Natl. Acad. Sci. 105 (2008), 13421–13426.
41. [41] De Craene, B., Berx, G., Regulatory networks defining EMT during cancer initiation and progression. Nat. Rev. Cancer 13 (2013), 97–110.